In a compact clinical trial at the University of Pittsburgh, four liver transplant recipients stopped taking anti-rejection drugs entirely and remained medication-free for an average of three years, with stable health outcomes.
The trial, detailed in a study published Friday in Nature Communications, involved 13 patients who received living donor livers and were given an infusion of their donor’s regulatory dendritic cells one week before transplantation. These cells, derived from white blood cells, are designed to train the immune system to tolerate the transplanted organ as self rather than foreign tissue.
After a year on standard immunosuppressants, researchers attempted to wean eight patients off the drugs based on signs of immune tolerance. While one patient eventually resumed medication, three maintained drug-free status throughout the study period, demonstrating sustained tolerance without graft rejection or significant health complications.
The approach builds on decades of research into immune tolerance as the “holy grail” of transplant medicine, aiming to eliminate the lifelong need for immunosuppressants that increase infection risk, cause kidney damage, and contribute to metabolic disorders like diabetes.
For more on this story, see Semaglutide and GLP-1 Drugs Show Efficacy Against Metabolic Liver Disease.
Unlike previous attempts using regulatory T cells, this method leverages regulatory dendritic cells’ unique ability to communicate with and modulate broader immune responses, offering a potentially more durable solution for inducing transplant tolerance.
Living donor liver transplants were chosen for the trial due to the organ’s regenerative capacity and its relatively lower immunogenicity compared to other organs, making it an ideal model for testing tolerance-inducing strategies in humans.
Researchers emphasize that while the results are promising, the study remains preliminary and small-scale, requiring larger trials to confirm long-term safety and efficacy before clinical adoption.
This follows our earlier report, ESBL E. coli Necrotizing Fasciitis After Liver Transplant.
How do regulatory dendritic cells differ from regulatory T cells in promoting transplant tolerance?
Regulatory dendritic cells are antigen-presenting cells that actively modulate immune responses by interacting with T cells and other immune components, whereas regulatory T cells primarily suppress immune activity through direct inhibition; dendritic cells may offer broader immune modulation capabilities in the context of transplant tolerance.
Why were living donor liver transplants selected for this trial instead of other organ types?
Living donor liver transplants were chosen because the liver has a greater capacity for immune tolerance compared to other organs, and its regenerative property allows for safe donation of a partial organ, making it a practical model for studying tolerance-inducing therapies in human transplantation.
